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Abstract
Adjuvant drugs for peripheral nerve blocks are a promising solution to acute postoperative pain and the transition to chronic pain
treatment. Peripheral nerve blocks (PNB) are used in the brachial plexus, lumbar plexus, femoral nerve, sciatic nerve, and many
other anatomic locations for site-specific pain relief. However, the duration of action of a PNB is limited without an adjuvant drug.
The use of non-opioid adjuvant drugs for single-shot peripheral nerve blocks (sPNB), such as alpha-2 agonists, dexamethasone, mi-
dazolam, and non-steroidal anti-inflammatory drugs, can extend the duration of local anesthetics and reduce the dose-dependent
adverse effects of local anesthetics. Tramadol is a weak opioid that acts as a central analgesic. It can block voltage-dependent sodium
and potassium channels, cause serotonin release, and inhibit norepinephrine reuptake and can also be used as an adjuvant in PNBs.
However, tramadol’s effectiveness and safety as an adjuvant to local anesthetic for PNB are inconsistent. The effects of the adjuvants
on neurotoxicity must be further evaluated with further studies to delineate the safety in their use in PNB. Further research needs
to be done. However, the use of adjuvants in PNB can be a way to help control postoperative pain.
Keywords: Peripheral Nerve Block, Postoperative Pain, Adjuvant Medications, Alpha-2 Agonists, NSAIDs, Dexamethasone,
Midazolam
1. Introduction
Opioids are the most commonly prescribed analgesia
in the postoperative period (1). The overreliance on opioids
for pain management has resulted in the quadrupling of
deaths from prescription opioids since 1999 (2). Although
opioids are an effective treatment in the postoperative set-
ting, the addictive potential makes it challenging to tran-
sition away from their use during chronic pain manage-
ment. Alternative pain treatments are necessary because
patients with chronic pain have a higher incidence of cog-
nitive decline and early death (3). Furthermore, the esti-
mated cost associated with chronic pain is $600 billion an-
nually in the US alone (3). In an effort to reduce the re-
liance on opioid treatment and reduce the morbidity of
chronic pain, adjuvant drugs for peripheral nerve blocks
are a promising solution to acute postoperative pain and
the transition to chronic pain treatment (4).
The pathophysiology of pain is complex and involves
both peripheral and central nervous system sensitization,
ascending and descending nervous system pathways, and
overlapping regions within the brain (2). Current research
targets numerous pathways within the complex physio-
logical pathway of nociception. The likelihood of transi-
tioning to chronic postsurgical pain has numerous risk fac-
Copyright © 2021, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License
(http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly
cited.
Edinoff AN et al.
tors, including age, gender, obesity, surgery duration, type
of anesthesia, and psychological factors (2). Genetic muta-
tions involving the COMT, OPRM1, GCH1, and other genes
likely play a role in chronic postsurgical pain (2). Improve-
ments in genetics, neurophysiological characterization of
patients, and pharmacokinetics of drugs enable better in-
dividualized non-opioid treatments of acute and chronic
pain (5). Individualized selection of adjuvant drugs used
with peripheral nerve blocks (PNB) has the potential to im-
prove patient outcomes.
Patient outcomes are further improved with advances
in ultrasound technology that enables precision-guided
techniques for peripheral nerve blocks (6). PNBs are used
in the brachial plexus, lumbar plexus, femoral nerve, sci-
atic nerve, and many other anatomic locations for site-
specific pain relief. However, the duration of action of a
PNB is limited without an adjuvant drug. For example, the
average duration of lidocaine and mepivacaine is two to
three hours (6). Clonidine, an alpha-2 agonist, increases
the duration of the nerve block by two hours in compar-
ison to a local anesthetic alone (6). For longer-term pain
control, continuous peripheral nerve blocks (CPNB) pro-
vide site-specific anesthesia and reduce or eliminate the
use of opioids (7). Although CPNBs are effective for longer
duration pain relief, the catheter is difficult to insert, it can
dislodge, and there is an additional cost (8). For these afore-
mentioned reasons, a single-shot peripheral nerve block
with adjuvant drugs to extend the duration of action is
commonly favored.
The use of adjuvant drugs for single-shot peripheral
nerve blocks (sPNB), such as alpha-2 agonist, dexametha-
sone, midazolam, and non-steroidal anti-inflammatory
drugs (NSAIDs), extends the duration of local anesthetics
and reduces the dose-dependent adverse effects of local
anesthetics (9). However, dose-dependent effects of local
anesthetics are not eliminated with adjuvant drug use. Ad-
ditionally, adjuvant drugs can also have dose-dependent
neurotoxic effects. A severe adverse effect of local anesthet-
ics is local anesthetic systemic toxicity (LAST). Additional
risks of the PNB include hematoma, infection, and periph-
eral nerve injury (1). Despite these risks, sPNBs are a suit-
able option for patients who are at high risk of respira-
tory depression, opioid addiction, opioid-induced nausea,
and vomiting or are not responsive to oral medications (6).
Alpha-2 agonists, dexamethasone, midazolam, and non-
steroidal anti-inflammatory drugs are efficacious adjuvant
drugs that require additional research on their safety (10-
14).
2. Alpha-2 Adrenergic Agonists (A2AA)
2.1. Clonidine
Clonidine is a commonly used alpha-2-adrenergic ag-
onist in regional anesthesia (14). It has been used as a
perineural adjunct to local anesthetics (LA) for peripheral
nerve block (PNB) since 1991 to effectively prolong block du-
ration and improve postoperative analgesia (15, 16).
The proposed mechanism for clonidine’s action in PNB
involves A-alpha (motor) and C (pain) fibers, which have
cation currents that restore the resting potential after hy-
perpolarization to allow for the next action potential gen-
eration (17). Clonidine might inhibit these currents by in-
creasing potassium conduction, thus blocking conduction
of the pain fibers and prolonging the duration of the local
anesthetic action (18, 19). It more strongly inhibits C fibers
than A-alpha fibers, resulting in more sensory-specific ef-
fects than motor ones (17). Additionally, clonidine might
also be delaying local anesthetic removal and enhancing
its action by vasoconstriction (18, 19).
Pöpping et al.’s 2009 meta-analysis found that 30 -
300µg of clonidine used as a perineural adjunct with LA
in PNB prolongs the duration of postoperative analge-
sia by about 2 hours; while this increase is independent
of LA type, the relative gain was markedly higher with
intermediate-acting LAs (56%) over long-acting LAs (18%)
(16). The study found the motor and sensory blocks to be
prolonged by 2.5 h and 1.25 h, respectively (16).
Clonidine can cause hemodynamic instability owing
to its antihypertensive nature and result in bradycardia, ar-
terial and orthostatic hypotension, sedation, rebound hy-
pertension, and syncope (20-22). A controlled dosage of 0.5
µg/kg up to a maximum of 150 µg is recommended to pre-
vent such side effects, but an optimal perineural clonidine
dose is yet to be determined (17, 19). Clonidine is Federal
Drug Administration (FDA)-approved for intrathecal and
epidural uses, but its safety for PNB usage is considered to
be “grandfathered” and generally accepted in anesthesia
(23).
2.2. Dexmedetomidine
Dexmedetomidine is a newer alpha-2 agonist that has
an eight-fold higher alpha-2 selectivity than clonidine,
with an alpha-2: alpha-1 receptor specificity of 1,600:1 and
a safer side effect profile (20, 24-26). Its sedative, anxiolytic,
and analgesic properties suitably position DEX as a non-
opioid adjuvant to local anesthetics (27-31).
The proposed mechanism for perineural dexmedeto-
midine in PNBs as first studied in rat models is simi-
lar to that of clonidine, which relies not on alpha-2 ago-
nism mechanism, but instead blocks hyperpolarization-
activated Ih cation currents and causes vasoconstriction
2 Anesth Pain Med. 2021; 11(3):e117197.
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for prolonged analgesia (27-32). Perineural dexmedetomi-
dine adjunct use is off-label, and proper risk-benefit analy-
sis, especially in patients where bradycardia and hypoten-
sion would be concerning, would be necessary before even
more widespread use of dexmedetomidine in PNBs can be
expected (17, 33-35).
While both clonidine and dexmedetomidine could
moderately prolong PNB, they both have the potential for
causing hypotension and bradycardia at higher doses, war-
ranting caution in their usage (13, 36). However, these two
alpha-2-agonists could promise to be useful in multimodal
perineural analgesia regimens (36, 37).
2.3. Dexamethasone
Dexamethasone is a glucocorticoid that is commonly
used to decrease the body’s inflammatory response. Doses
of 1, 2, 4, and 8 mg have been used as an adjuvant in inter-
scalene, supraclavicular, ankle, and brachial plexus blocks
(6). However, when dexamethasone is used as an adjuvant
in a PNB, the specific mechanism of action is unknown
(38, 39). Dexamethasone may produce extended analgesia
through vasoconstriction and reduced absorption of local
anesthetic or through “direct action on the nerve cell to re-
duce neural discharge” (8).
Despite having an unknown mechanism, a Cochrane
review of 35 trials of 2702 participants determined that
perineural dexamethasone adjuvant increased sensory
block 6.7 hours (95% confidence interval) in comparison
to a placebo (8). Similarly, intravenous dexamethasone
increased sensory block 6.2 hours in comparison to a
placebo. The Cochrane review also determined that the
cumulative 24-hour opioid consumption was significantly
reduced for both the perineural and intravenous dexam-
ethasone (19.25 mg reduction and 6.58 mg reduction, re-
spectively) (8). Of note, De Oliveira’s (2014) quantita-
tive review determined that perineural dexamethasone de-
creased postoperative opioid consumption when bupiva-
caine or ropivacaine was used, but not when lidocaine was
used (40). Although the Cochrane review demonstrated,
perineural dexamethasone is superior to intravenous dex-
amethasone in extending the duration of a spinal block,
Zhao (2017) determined (through a systemic review and
meta-analysis of RCTs) that perineural dexamethasone can
prolong the PNB effects only when epinephrine is co-
administered (41). Epinephrine is a well-known adjuvant
that increases the duration of local anesthetic through
vasoconstriction. Zhao (2017) suggests that epinephrine
and dexamethasone have a synergistic effect on extending
perineural PNB duration. In terms of controlling late post-
operative pain, most studies agree that the use of dexam-
ethasone as an adjuvant has no significant effect on pain
beyond 24 - 48 hours. The Cochrane review shows a sig-
nificant decrease in pain with perineural administration
at 12- and 24-hours post-surgery (no significant difference
between placebo and dexamethasone adjuvant at the 48-
hour mark) (8). In contrast, the De Oliveira review shows
that a dexamethasone adjunct is ineffective, in comparison
to the placebo, beyond 24 hours post-surgery (40).
Despite the relative agreement on the efficacy of dex-
amethasone, the safety profile has not been adequately
studied. Gagne (2021) expands on the Cochrane review and
examines nerve deficits beyond one month after surgery.
The results of the Gagne (2021) study show that 62% of
dexamethasone recipients had a nerve deficit, and 59% of
the ropivacaine-only PNB patients had a nerve deficit at
the two-week visit (42). At the six-month follow-up visit,
65% of the patients that had a nerve deficit in the dexam-
ethasone group had not fully recovered, and 40% of the
ropivacaine-only nerve deficit group had not recovered.
The Gagne (2021) study shows “a 2-fold increased risk of de-
layed recovery when perineural dexamethasone was used
as an adjunct” (42). Due to potential neurotoxicity and an
inadequate understanding of the mechanism of action of
dexamethasone, intravenous administration is preferable
(43).
2.4. Midazolam
Midazolam is a short-acting benzodiazepine, chiefly
used preoperatively as an anxiolytic agent and a sedative
and also often employed in diagnostic and surgical pro-
cedures to induce sleep (12, 43, 44). The data for the use
of midazolam as an adjunct to local anesthetics in periph-
eral nerve blocks are limited in the field’s current literature
landscape (45). Midazolam could be a promising adjuvant
owing to its ability to maintain the patient’s hemodynam-
ics (unchanged blood pressure and heart rate), relatively
low costs, rapid action onset, and metabolic clearance that
is better than other benzodiazepines that could warrant its
further characterization (46, 47).
The proposed mechanism for midazolam-induced
nerve block involves it acting at the translocator protein
(TPSO) (48). This has replaced the previous idea of midazo-
lam acting on peripheral g-aminobutyric acid or GABA-A
receptors, which are involved in producing midazolam’s
properties of sedation, anti-anxiety, and anterograde
amnesia (44).
Midazolam has a weak interaction with the kappa opi-
oid receptors, suggesting that it can play a part in pain con-
trol (49). Its action on the limbic system relieves negative
emotions of anxiety and fear during surgery, and this re-
duction of the patient’s psychological stress response, in
turn, lowers the risk of cardiovascular and cerebrovascu-
lar accidents (44). Midazolam can be extremely useful in
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upper extremity surgical procedures by helping block con-
duction of pain signals, prolong block duration, and par-
ticularly help with pain due to brachial plexus block (BPB)
insufficiency through its analgesic and sedative properties
(44). Midazolam usage as an adjuvant in PNB is discussed
further in a later section.
3. Tramadol and Non-steroidal Anti-inflammatory
Drugs (NSAIDs)
3.1. Tramadol
Tramadol is a weak opioid that acts as a central anal-
gesic (50). It can block voltage-dependent sodium and
potassium channels, cause serotonin release, and inhibit
norepinephrine reuptake (36, 51). When administered par-
enterally or orally, tramadol effectively aids in managing
acute postoperative pain in adults (52, 53). It can also pro-
duce a local anesthetic effect in blocking motor and noci-
ceptive function or act as an adjuvant in peripheral nerve
blocks to prolong sensory and motor block effects (36, 50).
This analgesic can inhibit pain either through aµ-receptor-
mediated opioid action or anα2-adrenergic and serotonin-
ergic non-opioid action (52, 53). Tramadol usage as an ad-
juvant in PNB is discussed further in a later section.
3.2. NSAIDs
Non-steroidal anti-inflammatory drugs (NSAIDs) have
been used for many decades for their analgesic, anti-
inflammatory, and antipyretic properties. They can be a
better perioperative adjuvant choice than opiates for their
ability to produce effective analgesia without causing res-
piratory depression (54, 55). NSAIDs block prostaglandins
synthesis by inhibiting cyclooxygenase (COX) 1 and 2, thus
limiting downstream cytokine release and reducing the in-
flammatory response (18, 56).
3.3. Parecoxib
Parecoxib sodium is a highly selective COX-2 inhibitor
that is favored as an adjunct in acute postoperative man-
agement (55). It reduces postoperative pain, opioid con-
sumption, and drug-related adverse reactions that all ac-
celerate postoperative patient recovery (55). A 2019 study
by Qiao et al. investigated intravenous parecoxib sodium
in a transverse abdominis plane (TAP) block in patients
who underwent hepatectomy for hepatocellular carci-
noma (56). The use of parecoxib significantly lowered
pain scores without significant adverse events, showing
the safety of the drug and efficacy in managing acute post-
operative pain when used as an adjuvant for TAP periph-
eral nerve block (56). It is important to note that parecoxib
is not FDA approved for use in the USA. However, it is ap-
proved in Europe.
3.4. Ketorolac
Ketorolac prolongs local anesthesia action in regional
anesthesia by inhibiting prostaglandin synthesis, and a
dosage of 20 - 60 mg has been shown to benefit postopera-
tive analgesia when used as a part of intravenous regional
anesthesia (IVRA) (57, 58). Use of this drug with local anes-
thetic lidocaine in a peripheral nerve block for foot surgery
increased analgesia duration and quality (59). However,
ketorolac as an adjuvant in infraclavicular BPB could not
prolong the duration of motor and sensory blocks and
quicken their onset and dexmedetomidine (57). These re-
sults were consistent with the Budnyk et al. study, where
ketorolac could not increase sensory and motor block du-
ration when used as an adjuvant to bupivacaine in BPB (57).
Adjunct usage of NSAIDs is more widely explored in
IVRA than in peripheral nerve blocks. In addition to ketoro-
lac, paracetamol, and dexketaprofen added to lidocaine,
prolonged motor and sensory blocks quickened their on-
set and reduced analgesic consumption (60). Similar bene-
fits with adjunct use of NSAIDs like lornoxicam, tenoxicam,
and lysine acetylsalicylate in IVRA have also been demon-
strated (58). Perineural usage of NSAIDs in peripheral
nerve blocks is not recommended until further research
exploring their safety and efficacy and federal approval for
this purpose (18, 36).
4. Clinical Studies: Safety and Efficacy
4.1. Dexmedetomidine
Evidence for dexmedetomidine as an adjunct for PNB
is the strongest for BPB (61). As supported by a 2017 meta-
analysis of 34 trials, perineural dexmedetomidine adjunct
use in BPB effectively prolonged duration of analgesia by
4.5 h and motor and sensory blocks by 3 and 4 h, respec-
tively, and decreased onset time of sensory block by 9 min
and motor block by 8 min (62). A 2018 meta-analysis of
46 trials showed significant prolongation of postoperative
analgesia by 5 h and motor blockade by 4 h in 25 to 150 µg
perineural dexmedetomidine administration with long-
acting LA in PNB (35).
Dexmedetomidine has been shown to prolong analge-
sia duration when added to bupivacaine, levobupivacaine,
or ropivacaine for PNBs (63). A recent study investigated
the efficacy of dexmedetomidine as an adjunct by compar-
ing its use with ropivacaine in interscalene brachial plexus
block (ISBs) versus only ISB for patients undergoing arthro-
scopic rotator cuff repair (63). The authors found the com-
bination of dexmedetomidine and ISB significantly de-
creased postoperative visual analog scores (VAS) and signif-
icantly increased patient satisfaction scores (SAT) within
the first 48 postoperative hours compared to the control
4 Anesth Pain Med. 2021; 11(3):e117197.
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group (63). Additionally, dexmedetomidine also showed
lower mean levels of interleukin 6 and 8 and delayed re-
bound pain (63). Given that ISB has a relatively short du-
ration of effect, despite being one of the most powerful
regional blocks for shoulder procedures, prolonged anal-
gesia due to dexmedetomidine being an effective adju-
vant to ropivacaine is highly beneficial in PNBs. A related
study that compared dexmedetomidine with ropivacaine
in a suprascapular nerve block (SSNB) and axillary nerve
block (ANB) to only SSNB and ANB again found significantly
lower VAS, higher SAT scores with the adjunct use, and
delayed rebound pain (52). Given that SSNB is the most
prevalent method for pain control in arthroscopic shoul-
der surgery, dexmedetomidine effectively enhancing the
block as an adjuvant to LA in peripheral nerve blocks is
promising (52).
The efficacy of dexmedetomidine as an adjuvant has
also been evaluated in TAP block, where it has proved use-
ful in enhancing block duration in many surgical pro-
cedures (64). 1µg/kg of dexmedetomidine with 20 mL
of 0.125% bupivacaine in TAP in laparoscopic appendicec-
tomy, compared to only bupivacaine, prolonged postoper-
ative analgesia (7.33 vs. 4.8 h), and reduced the number of
patients who needed rescue analgesics (56.7 vs. 80%).(66)
Pain scores were significantly lower with dexmedetomi-
dine at 2, 4, 6, and 24 h post-surgery (but comparable at 8
and 12 h timepoints) (64). The authors claimed that there
is no difference in the safety profile of dexmedetomidine
versus the control group and reported no additional risk
of hemodynamic instability (64). Ultimately, the authors
conclude dexmedetomidine to be a safe and effective adju-
vant for TAP block. These results are consistent with a 2019
meta-analysis, which investigated the same in abdominal
surgery patients and found dexmedetomidine to signifi-
cantly reduce postoperative pain and opioid use and pro-
long sensory block in TAP block (65). It found no difference
in the incidence of bradycardia, hypotension, postopera-
tive nausea, and vomiting, etc (65).
The 2018 meta-analysis also showed up to three times
higher risk of intraoperative hypotension and bradycardia
with perineural dexmedetomidine over placebo, an asso-
ciation that should be evaluated cautiously owing to the
low quality of evidence (35). The 2017 meta-analysis too re-
ported transient and reversible side effects of bradycardia
and hypotension (62). Neurotoxicity data for dexmedeto-
midine is inconsistent (19).
A dosage of 50 - 60 µg dexmedetomidine is recom-
mended in BPB to maximize sensory block duration while
minimizing hemodynamic side effects (61, 62). While a
similarly strong recommendation for other PNBs is lack-
ing and necessitating more dose-comparison studies, the
literature consensus is 1 µg/kg dexmedetomidine to pro-
long peripheral nerve blockade by 200 min (36, 51). Meta-
analyses suggest that dexmedetomidine is a stronger anal-
gesic than clonidine but weaker than non-steroid inflam-
matory drugs; perineural dexmedetomidine is superior to
clonidine but inferior to dexamethasone in terms of block
characteristics indices and also has a greater risk of hy-
potension and sedation than dexamethasone (37, 66).
Any perineural applications of dexmedetomidine have
been off-label, and special attention must be paid to the
safety of the medication (67). FDA does not approve its pe-
ripheral administration (68). Adverse events, most com-
monly bradycardia and hypotension, have been mostly
documented in adjuvant use of dexmedetomidine in BPB
(67). Meta-analysis suggests that a dosage of more than 50
µg increases the risk for bradycardia (68). More large ran-
dom controlled trials focusing on adverse events caused by
dexmedetomidine as an adjuvant in PNBs are necessary to
further characterize the safety of the drug.
4.2. Dexamethasone
Dexamethasone is one of the most studied and exten-
sively used adjuvants administered to prolong peripheral
nerve blockade duration with local anesthetics (69). It is
believed to prolong PNB duration better than local anes-
thetics alone and increase sensory blockade (70, 71).
Perineural dexamethasone use in peripheral nerve
block increases mean analgesia duration by about 1.5h and
decreases opioid consumption by 7 mg at 24h and postop-
erative pain scores at 12h and 24h (19). It is most thoroughly
evaluated for brachial plexus block in the literature, where
4mg of the additive has been reported to be the lowest suf-
ficient dose in PNB (19, 69, 72).
As an adjuvant for supraclavicular brachial plexus, dex-
amethasone prolongs motor and sensory blockade with
bupivacaine and levobupivacaine (72). A 2019 random con-
trolled trial investigated 4 mg of dexamethasone with 3 mL
of 0.56% ropivacaine found no beneficial effect in prolong-
ing sensory block in a standard peripheral block, in either
perineural or I.V. administration (69). At an 8 mg dose with
0.5% levobupivacaine for brachial plexus block in upper ex-
tremity surgery, it delayed requirement and time until res-
cue analgesia, quickened sensory and motor block onset,
and prolonged sensory and motor blockade duration (72).
A 2021 meta-analysis of 6 RCTs found no significant dif-
ference amongst dexamethasone and dexmedetomidine
for analgesia duration, sensory block onset, and motor and
sensory block duration in PNB (73) However, when com-
pared to dexmedetomidine, dexamethasone reduced fen-
tanyl analgesic consumption by about 29 µg (73). A 2020
study showed that 1 µg/kg dexmedetomidine or 8 mg dex-
amethasone as an adjuvant to 0.5% ropivacaine in supr-
aclavicular brachial plexus block significantly shortened
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motor and sensory onset, prolonged motor and sensory
block duration, and reduced 24h total analgesics, without
any significant difference between the two (74). However,
dexmedetomidine had better patient satisfaction owing
to more sedation than with dexamethasone (75). Dexam-
ethasone’s ability to enhance analgesia duration by more
than 6h is better than that achieved by adjuvants like cloni-
dine (71). Its usage with levobupivacaine is most favor-
able as it does not produce side effects associated with ad-
juvants of clonidine, dexmedetomidine, or opioids (72).
When compared to midazolam (2 mg) as an adjuvant for
0.5% bupivacaine in supraclavicular brachial plexus block,
dexamethasone (4 mg) produced significantly faster onset
of sensory and motor blocks, prolonged analgesia, sensory
and motor blocks duration, and lower VAS scores (75). As
Marhofer and colleagues highlight, despite several system-
atic reviews and meta-analyses to date, the efficacy of dex-
amethasone with local anesthetic in PNB is still uncertain
due to low-quality evidence (as addressed by the authors of
each themselves) and the high heterogeneity of the study
designs (59).
Dexamethasone is still off-label for peripheral admin-
istration (73). The safety profile of dexamethasone re-
mains open to debate (72). While some in-vitro studies
show peripheral neurotoxicity produced by dexametha-
sone, others show it mitigating bupivacaine-induced neu-
rotoxicity (69, 70). Large doses of dexamethasone (up to
133 µg/mL) can increase ropivacaine-induced neurotoxic-
ity, but at clinically relevant concentrations, this combina-
tion did not increase neurotoxicity (76). While dexametha-
sone does not disrupt hemodynamic variables or produce
any other adverse side effects, it could increase postopera-
tive glucose concentration after perineural or intravenous
administration (19, 75, 77). There are also concerns about lo-
calized nerve and muscle injury and inconsistent evidence
for perineural versus systemic administration regarding
dexamethasone use (19). Significantly higher rates of nerve
injury might not be detected until sample sizes are much
larger and conclusively show dexamethasone to be safe
(78). In their 2021 review, Desai and colleagues recommend
0.1 - 0.2 mg/kg of dexamethasone administered via the sys-
temic route for LA adjunct use in surgical procedures that
can involve significant postoperative pain (19). More dose-
finding studies are needed to determine the optimal dose
of dexamethasone (73). Ultimately, it is a promising adju-
vant candidate in peripheral nerve blocks and is likely the
best option to prolong analgesia over other candidates like
clonidine or midazolam (70).
4.3. Tramadol
Tramadol’s effectiveness and safety as an adjuvant to LA
for PNB are inconsistent (17, 19, 36, 51). Several studies and
systematic reviews have investigated tramadol as an adju-
vant in BPB but often yielded contradictory results (52, 79).
Reviews by Koyyalamudi et al. and Kirksey et al. investi-
gate tramadol with different local anesthetics (like bupiva-
caine, levobupivacaine, mepivacaine, and ropivacaine) in
various PNBs (interscalene, axillary brachial plexus) reveal
the often contradictory nature of the results (19, 36). Re-
cently, a 2019 RCT found that 100 mg tramadol with 0.5%
ropivacaine for interscalene BPB lowered pain scores and
cumulative morphine consumption 24h post-surgery (79).
The authors claimed that the low incidence of complica-
tions suggests the safety of tramadol-ropivacaine combi-
nation to improve postoperative analgesia (79). Won Shin
et al.’s 2017 meta-analysis of 16 RCTs reported 100 mg tra-
madol as prolonging sensory block, motor block and anal-
gesia (high-quality evidence), and quickening sensory and
motor block onsets for BPB in upper extremity surgeries
(52). Tramadol also did not change adverse events inci-
dence after BPB in their analysis (52). The findings for per-
ineural versus systemic administration and the potential
for neurotoxicity are still unclear (19, 36). While there have
been no reports of nerve damage due to tramadol, its per-
ineural administration is not FDA-approved and not rec-
ommended as an adjuvant in PNB (19, 51, 52).
4.4. Midazolam
A 2005 study by Jarbo and colleagues is primarily cited
in support of efficacious perineural adjunct use of mida-
zolam, where 50 µg/kg of the drug was used with 30 mL
of 0.5% bupivacaine LA for a supraclavicular BPB (80). The
authors reported enhanced onset of sensory and motor
blockade, reduction of pain scores, and postoperative anal-
gesia without any adverse effects (80). These results were
replicated by a 2008 study, where once again 50 µg/kg mi-
dazolam with 30 mL of 0.5% bupivacaine for supraclav-
icular BPB increased onset speed of sensory and motor
blocks, prolonged duration and quality of the blocks, and
enhanced analgesia (lower pain scores and fewer rescue
analgesics) (81). A 2020 study by Xu and colleagues strongly
recommends adjuvant use of midazolam in BPB for upper
limb surgery after finding benefits in its intravenous sup-
plementation (44). However, the interactions of midazo-
lam with the local anesthetic used in the procedures or the
potential for midazolam neurotoxicity were not discussed
in the study.
Besides in brachial plexus blocks, midazolam has also
lately been explored as an adjuvant to bupivacaine for a
TAP block. A 2019 prospective randomized control trial by
El Kenany and colleagues of this purpose reported a reduc-
tion in 24h morphine use and prolongation of postopera-
tive analgesia (47). They assuaged the concern of neurotox-
icity through the use of the established dosage of 50µg/kg
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of midazolam (but with 20 mL of 0.25% bupivacaine) that
has previously been proven to be safe (47). In their 2021 re-
view, Desai et al. describe the results for perineural effec-
tiveness of midazolam to be conflicting due to unclear evi-
dence about its benefits over systemic administration (52).
The authors ultimately did not recommend perineural use
of midazolam (19).
The greatest concern about midazolam adjuvant use
in PNB is its potential neurotoxicity (47). Multiple ani-
mal studies show intrathecal midazolam administration
to be neurotoxic and midazolam’s ability to significantly
worsen neuronal cytotoxicity when combined with LA (36,
45). Currently, adjuvant use of midazolam is not FDA-
approved and is strongly advised against being used per-
ineurally with LA in PNB until more high-quality safety
data is obtained (23, 36, 45, 51).
Interestingly, midazolam produces no in-vitro or
in-vivo neurotoxicity when used with a combination
of clonidine-buprenorphine-dexamethasone that lacks
any LA (23). Additionally, a 2015 study proposes that
midazolam-induced nerve block and its neurotoxicity are
separatable, where selectively activating the translocator
protein (TPSO) could minimize the potential for neurotoxi-
city (48). Until further research, midazolam as an adjuvant
in PNB is currently limited to use at an established dosage
with documented local anesthetics for this purpose.
5. Conclusions
Adjuvant drugs for peripheral nerve blocks are a
promising solution to acute postoperative pain and the
transition to chronic pain treatment. Many have shown
in studies to increase the length of time the block is ac-
tive and decrease the use of rescue pain medications in the
postoperative period. Clonidine and dexmedetomidine
are alpha-2 agonists that have been shown to prolong PNB.
Dexamethasone has been shown to work better than both
of the alpha-2 agonists. However, it shows no significant
effect on pain beyond 24 - 48 hours. Others include mida-
zolam, tramadol, and NSAIDs. Research on these adjuvants
is not robust, and so many of them are not FDA approved
as an adjuvant. The effects of the adjuvants on neurotoxic-
ity must be reviewed with further studies to delineate the
safety in their use in PNB. Their efficacy shows promise in
recent studies. Further research needs to be done. How-
ever, the use of adjuvants in PNB can be a way help control
postoperative pain.
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